Hologic Inc. currently faces headwinds with a significant year-over-year EPS decline of 23.76% and a missed earnings estimate of $1.042 versus $1.1138 in Q1 2026. Despite a market cap of $16.97B, the recent leadership shake-up with the hiring of CEO José Almeida may not be enough to stabilize the stock, especially given that only 1 out of 23 analysts rate it as a sell or strong sell.